tbuckley/cabot-search huggingface dataset:
Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.
Authors: R Donald Harvey, Nicolas Isambert, Saeed Rafii, Johan F. Vansteenkiste, Paul A. Dickinson, Khanh Bui, Doris Weilert, Karen So, Karen Thomas, Karthick Vishwanathan
Journal: Journal of Clinical Oncology (2016)

e14098 Background: Osimertinib is a potent, oral, irreversible EGFR-TKI with efficacy in pts with EGFR-TKI sensitizing (EGFRm) and T790M mutation positive advanced NSCLC. In vitro data show osimertinib induces and/or inhibits cytochrome P450 (CYP)3A and inhibits breast cancer resistance protein (BCRP) transporters. We report results (Part A) from 2 Phase I open-label, 2-part clinical studies designed to evaluate the effects of osimertinib on simvastatin (sensitive CYP3A4 substrate; Study 14; NCT02197234) or rosuvastatin (BCRP substrate; Study 19; NCT02317016) in pts with EGFRm NSCLC following disease progression on a prior EGFR-TKI. Part B (ongoing) further evaluates pt safety on osimertinib. Methods: Part A evaluated the effect of multiple oral doses of osimertinib on the single-dose PK of simvastatin or rosuvastatin and pt safety. In Study 14, pts received a single dose of simvastatin 40 mg po on Days 1 and 31 and osimertinib (80 mg once daily [qd]) on Days 3–32. In Study 19, pts received a single dose of rosuvastatin 20 mg po on Days 1 and 32 and osimertinib (80 mg qd) on Days 4–34. Blood samples were taken to determine concentrations of simvastatin, simvastatin acid or rosuvastatin, and osimertinib and its active metabolites (AZ5104 and AZ7550). 2-sided 90% CIs for AUC and Cmax ratios were to be within 70–143% to conclude no effect on the PK of simvastatin or rosuvastatin after administration of osimertinib. Results: Forty-eight of 52 and all 44 treated pts were included in the statistical comparisons in Study 14 and Study 19, respectively. Geometric least squares mean (GLSM) ratios (90% CIs) of simvastatin (simvastatin + osimertinib / simvastatin alone) AUC and Cmax were 91% (77–108) and 77% (63–94), respectively. GLSM ratios of rosuvastatin (rosuvastatin + osimertinib / rosuvastatin alone) AUC and Cmax were 135% (115–157) and 172% (146–203), respectively. Osimertinib was well tolerated with reported adverse events consistent with its known safety profile. Conclusions: Daily administration of osimertinib increased rosuvastatin exposure, and had minimal effect on simvastatin exposure, indicating that osimertinib has an inhibitory effect on BCRP but is unlikely to affect the PK of CYP3A4 substrates. Clinical trial information: NCT02197234 and NCT02317016.
Intérêt pronostique de l'échoendoscopie (EE) dans le traitement et le suivi des tumeurs carcinoïdes rectales (TCR) de petite taille
Authors: B Pujol, J Desramé, C Lefort, J Fumex, B Napoléon
Journal: Endoscopy (2009)

Introduction: Les TCR sont rares (0,7 à 2% des tumeurs rectales), le plus souvent de découverte fortuite, avec un risque métastatique corréléà l'histologie et à 2 critères évalués en EE: la taille et l'extension pariétale. Pour les TCR de petite taille (≤1cm) ce risque est de 2% si l'extension est limitée à la sous muqueuse et 50% si atteinte de la muscularis propria (MP). L'exérèse idéale se fait par mucosectomie (M) ou chirurgie transanale (CTA). En pratique, des lésions polypoides sont fréquemment enlevées partiellement à l'anse (A) ou à la pince à biopsie (PB). Le risque de récidive locale (RL) ou d'extension métastatique est alors plus difficile à apprécier.
PROXIMAL ADENOMAS AND COLORECTAL CANCER: TWO SHADOWS IN THE EFFECTIVENESS OF COLONOSCOPIC SURVEILLANCE
Authors: L Adán Merino, M Aldeguer Martínez, F Valentín Gómez, J Barrio Antoranz, R Plaza Santos, C Zaera de la Fuente, F Garrido Gallego
Journal: Endoscopy (2018)

Postpolypectomy and operated colorectal cancer (CRC) endoscopic surveillance is the best way to identify metachronous lesions.
Collagen deposition in chronic hidradenitis suppurativa: potential role for CD163<sup>+</sup> macrophages
Authors: A.S. Byrd, M.L. Kerns, D.W. Williams, J.C. Zarif, A.Z. Rosenberg, M. Delsante, H. Liu, C. A. Dillen, J.P. Maynard, J.A. Caffrey, J.M. Sacks, S.M. Milner, O. Aliu, K.P. Broderick, L.S. Lew, L.S. Miller, S. Kang, G.A. Okoye
Journal: British Journal of Dermatology (2018)
Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation
Authors: Jawad H. Butt, Ying Xian, Eric D. Peterson, Peter Skov Olsen, Rasmus Rørth, Anna Gundlund, Jonas B. Olesen, Gunnar H. Gislason, Christian Torp-Pedersen, Lars Køber, Emil L. Fosbøl
Journal: JAMA Cardiology (2018)

<h3>Importance</h3> New-onset postoperative atrial fibrillation (POAF) is a common complication of coronary artery bypass graft (CABG) surgery. However, the long-term risk of thromboembolism in patients who develop POAF after CABG surgery remains unknown. In addition, information on stroke prophylaxis in this setting is lacking. <h3>Objective</h3> To examine stroke prophylaxis and the long-term risk of thromboembolism in patients with new-onset POAF after first-time isolated CABG surgery compared with patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). <h3>Design, Setting, and Participants</h3> This cohort study used data from a clinical cardiac surgery database and Danish nationwide registries to identify patients undergoing first-time isolated CABG surgery who developed new-onset POAF from January 1, 2000, through June 30, 2015. These patients were matched by age, sex, CHA<sub>2</sub>DS<sub>2</sub>-VASc score, and year of diagnosis to patients with nonsurgical NVAF in a 1 to 4 ratio. Data analysis was completed from February 2017 to January 2018. <h3>Main Outcomes and Measures</h3> The proportion of patients initiating oral anticoagulation therapy within 30 days and the rates of thromboembolism. <h3>Results</h3> A total of 2108 patients who developed POAF after CABG surgery were matched with 8432 patients with NVAF. In the full population of 10 540 patients, the median (interquartile range) age was 69.2 (63.7-74.7) years; 8675 patients (82.3%) were men. Oral anticoagulation therapy was initiated within 30 days postdischarge in 175 patients with POAF (8.4%) and 3549 patients with NVAF (42.9%). The risk of thromboembolism was lower in the POAF group than in the NVAF group (18.3 vs 29.7 events per 1000 person-years; adjusted hazard ratio [HR], 0.67; 95% CI, 0.55-0.81;<i>P</i> &lt; .001). Anticoagulation therapy during follow-up was associated with a lower risk of thromboembolic events in both patients with POAF (adjusted HR, 0.55; 95% CI, 0.32-0.95;<i>P</i> = .03) and NVAF (adjusted HR, 0.59; 95% CI, 0.51-0.68;<i>P</i> &lt; .001) compared with patients who did not receive any anticoagulation therapy. Further, the risk of thromboembolism was not significantly higher in patients with POAF compared with those who did not develop POAF after CABG surgery (adjusted HR, 1.11; 95% CI, 0.94-1.32;<i>P</i> &lt; .24). <h3>Conclusions and Relevance</h3> New-onset POAF in patients who had undergone CABG surgery was associated with a lower long-term thromboembolic risk than that of patients who had NVAF. These data do not support the notion that new-onset POAF should be regarded as equivalent to primary NVAF in terms of long-term thromboembolic risk.
ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.
Authors: Yuksel Urun, Tulay Koru-Sengul, Kadri Altundag, Gungor Utkan, Handan Onur, Hakan Akbulut, Ahmet Demirkazik, Fikri Icli
Journal: Journal of Clinical Oncology (2012)

1572 Background: The role of genetic factors in the development of cancer is widely accepted. ABO blood type is an inherited characteristic and previous studies have observed an association between ABO blood group and risk of certain malignancies, including pancreatic and gastric cancer. The data on the role of ABO blood group and Rh factor in breast cancer is inconclusive. Methods: All patients who had breast cancer (BC) and treated between 2000-2010 at the Departments of Medical Oncology of both Ankara and Hacettepe Universities (Ankara, Turkey) with defined ABO blood type and Rh factor were included in our retrospective reviews of tumor registry records. A group of volunteer healthy women donors of Turkish Red Crescent between 2004-2011 were identified as a control group, without any matching factors. The relationship of ABO blood types and Rh factor with various prognostic factors such as age at diagnosis, menopausal status, family history of breast cancer, and ER/PR/HER2 status were evaluated from 1740 BC patients. We compared the distributions of ABO blood types, Rh factors among 1740 patients and 204,553 healthy controls. Among BC patients, differences between each of aforementioned ABO blood groups and Rh factors with respect to various prognostic factors were explored, respectively. Results: Overall distributions of ABO blood groups as well as Rh factor were comparable between patients (44% A, 8% AB, 16% B, 32% O, 88% Rh+) and controls (41% A, 8% AB, 16% B, 35% O, 87% Rh+). However, there were statistically significant differences between patients and controls with respect to A vs. nonA (p=0.019) and marginal significance (p=0.051) for O vs. nonO. Among patients, there were statistically significant differences between A and nonA with respect to HER2 (p=0.0421), M stage (p=0.0447), T stage (p=0.0020). Only T stage (p=0.0337) were significantly different between O vs nonO. Grade (p=0.0227) and M stage (p=0.0107) were significantly different between Rh factors. Conclusions: In our study sample, ABO blood type was statistically significantly associated with breast cancer. Additional studies are necessary to determine the mechanisms by which ABO blood type may influence the risk of breast cancer.
ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) OF GASTRIC AND RECTAL NEUROENDOCRINE TUMOURS (NETS): A CASE SERIES FROM A TERTIARY REFERRAL CENTRE (WITH VIDEO)
Authors: A Murino, A Telese, N Koukias, E Vlachou, C Toumpanakis, D Mandair, TV Luong, ME Caplin, EJ Despott
Journal: Endoscopy (2018)

Gastrointestinal (GI) neuroendocrine tumours (NETs) are potentially malignant lesions originating from GI neuroendocrine cells. Endoscopic submucosal dissection (ESD) is an advanced, complex endoscopic technique developed in Japan, which allows for en-bloc resection of mucosal and submucosal lesions.
Cardiovascular disease and multimorbidity: A call for interdisciplinary research and personalized cardiovascular care
Authors: Kazem Rahimi, Carolyn S. P. Lam, Steven Steinhubl
Journal: PLoS Medicine (2018)

In a Guest Editorial, Kazem Rahimi, Carolyn Lam, and Steven Steinhubl call for interdisciplinary research and personalized cardiovascular care to better manage patients with cardiovascular disease and multimorbidity.
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
Authors: Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner-Herold, Miriam J. Müller, Dietrich A. Volmer, Christian Bach, Mario Fabri, Jörg T. Bittenbring, Frank Neumann, Rainer Boxhammer, Jens Nolting, Savita Bisht, Martin Böttcher, Simon Jitschin, Markus H. Hoffmann, Heidi Balzer, Fabian Beier, Deniz Gezer, Diana Dudziak, Kolja Gelse, Friedrich F. Hennig, Christian P. Pallasch, Bernd Spriewald, Andreas Mackensen, Heiko Bruns
Journal: Leukemia (2018)
MULTICENTRIC ASSESSMENT OF THE ENDOSCOPIC MANAGEMENT OF SUPERFICIAL ESOPHAGEAL SQUAMOUS-CELL CARCINOMA IN WESTERN POPULATION
Authors: A Berger, G Rahmi, G Perrod, M Pioche, JM Canard, E Cesbron-Métivier, J Boursier, E Samaha, A Vienne, V Lépilliez, C Cellier
Journal: Endoscopy (2018)

Evaluation of the endoscopic resection efficiency for superficial esophageal SCC and long-term outcom.
Activated renal tubular Wnt/β-catenin signaling triggers renal inflammation during overload proteinuria
Authors: Dickson W.L. Wong, Wai Han Yiu, Kam Wa Chan, Ye Li, Bin Li, Sarah W.Y. Lok, Makoto M. Taketo, Peter Igarashi, Loretta Y.Y. Chan, Joseph C.K. Leung, Kar Neng Lai, Sydney C.W. Tang
Journal: Kidney International (2018)
IS LUGOL NECESSARY FOR ENDOSCOPIC RESECTION OF SQUAMOUS CELL NEOPLASIA OF THE ESOPHAGUS?
Authors: A Ferreira, C Mouradides, E Cuadrado Robles, R Yeung, R Duran, C Snauwaert, A Mourin-Jouret, H Piessevaux, P Deprez
Journal: Endoscopy (2018)

Mucosal chromoendoscopic enhancement with Lugol solution improves the sensitivity for squamous cell carcinoma (SCC) diagnosis. However, it is time-consuming and associated with increased esophageal motility which may difficult endoscopic resection. Narrow band imaging (NBI) is easier to use and has been shown to be useful for SCC diagnosis. Our aim was to assess the effectiveness of Lugol when compared to NBI for lesion demarcation in esophageal SCC.
Associations Between Changes in Depressive Symptoms and Social Support and Diabetes Management Among Low-Income, Predominantly Hispanic Patients in Patient-Centered Care
Authors: Hyunsung Oh, Kathleen Ell
Journal: Diabetes Care (2018)

OBJECTIVE This study examined whether changes in depressive symptoms and social support prospectively predicted diabetes management among Hispanic patients with probable depression in patient-centered medical homes at safety-net clinics in East Los Angeles, CA. RESEARCH DESIGN AND METHODS Data were collected from 251 patients enrolled in a randomized clinical trial testing the effectiveness of a self-management intervention assisted by a promotora (Hispanic community health worker). Cross-lagged analyses examined associations between changes in depression symptoms and social support between baseline and 6-month follow-up and self-efficacy and adherence to diabetes management at the 6- and 12-month follow-ups. RESULTS Changes in depressive symptoms predicted self-efficacy and level of adherence at the 6- and 12-month follow-ups. Changes in total social support and emotional social support were correlated only with self-efficacy regarding diabetes management at 6-month follow-up. CONCLUSIONS Decline in depressive symptoms is a reliable predictor of improvement in self-efficacy and adherence to diabetes management. Further studies are recommended to study psychosocial mechanisms related to social relationships other than social support that affect diabetes management.
Endomicroscopie avec fluorescence en pathologie digestive: étude pilote multicentrique française
Authors: E Coron, JF Mosnier, JC Saurin, V Sébille, C Pesenti, J Moreau, M Antonietti, JP Galmiche
Journal: Endoscopy (2009)

Introduction: L'endomicroscopie est une nouvelle technique d'imagerie à l'échelle subcellulaire permettant l'acquisition de biopsies optiques au cours de l'endoscopie. L'injection intraveineuse de fluorescéine est couramment utilisée mais expose à un risque rare d'événement indésirable grave. Le but de cette étude prospective multicentrique était d'évaluer 1) la tolérance de l'examen, et 2) la faisabilité de la mise en place standardisée de la technique afin d'obtenir des biopsies optiques exploitables.
ESOMEPRAZOLE VS RABEPRAZOLE IN THE HEALING OF ARTIFICIAL ULCERS AFTER THE ENDOSCOPIC SUBMUCOSAL DISSECTION USING THE CLUTCH CUTTER: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY
Authors: K Akahoshi, S Nagatomo, S Osada, E Yamaguchi, M Kubokawa, J Gibo, K Yodoe, K Inamura, K Akahoshi, Y Shiratsuchi
Journal: Endoscopy (2018)

Clinical course of post-endoscopic submucosal dissection (ESD) gastric ulcer (PESDGU) is affected by ESD method including kinds of devices and endoscopist's skill. There were no previous reports on the efficacy of proton pump inhibitors for PESDGU healing in patients who underwent single device ESD method by single endoscopist. This prospective randomized controlled study compared the efficacy and safety of esomeprazole (EM) with rabeprazole (RB) in PESDGU healing in the patients who underwent single device ESD method by single endoscopist.
IS COMPRESSION OF THE COMMON BILE DUCT BY THE RIGHT HEPATIC ARTERY A POTENTIAL CAUSE OF INTRAHEPATIC STONES?
Authors: V Perri, V Bove, A Tringali, I Boškoski, B Federico, R Landi, P Familiari, G Costamagna
Journal: Endoscopy (2018)

In 80% of patients the hepatic artery courses between the extrahepatic bile duct and the portal vein. Variations of normal course of the hepatic arteries have already been described as responsible for the onset of jaundice. We present three cases of patients with intrahepatic stones and compression of the common bile duct (CBD) by the right hepatic artery.
ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR EARLY BARRETT'S CANCER – DOES R0 RESECTION MATTER?
Authors: S Subramaniam, A Alkandari, S Thayalasekaran, G Longcroft-Wheaton, P Bhandari
Journal: Endoscopy (2018)

The role of ESD in the resection of early Barrett's cancer is evolving with increasing expertise. It has advantages over endoscopic mucosal resection (EMR) as en bloc resection is enabled, even in scarred or submucosally invasive lesions. However, the R0 resection rate may be affected by the technical difficulty of ESD compared to EMR. Following endoscopic resection, ablative treatment is given to patients eligible for endoscopic follow up. The aim of our study was to evaluate the en bloc and R0 resection rate of ESD in Barrett's neoplasia and its association with outcomes.
IMPACT OF A DEDICATED MULTIDISCIPLINARY MEETING ON THE MANAGEMENT OF SUPERFICIAL CANCERS OF THE DIGESTIVE TRACT
Authors: M Barret, S Dermine, C Prieux, S Ribière, S Leblanc, B Terris, B Dousset, P Soyer, A Dohan, JE Bibault, R Coriat, F Prat, S Chaussade
Journal: Endoscopy (2018)

A multidisciplinary meeting (MDM) should be incorporated into the management of all patients with cancer. However, conventional gastrointestinal oncology MDM might not be optimal to discuss these patients’ cases. We aim to assess the contribution to patient care of an MDM dedicated to superficial cancers of the digestive tract.
POST PROCEDURE EFFICACY, COMPLICATIONS AND BENEFITS OF HET – HEMORRHOIDAL ENERGY TREATMENT: A SINGLE-CENTER EXPERIENCE
Authors: T Kothari, K Bittner, S Kothari, V Kaul, M Sharma
Journal: Endoscopy (2018)

Efficacy would include resolution of bleeding. Complications would include fecal incontinence and stricture formation in anal canal. Benefits include improvement and total resolution of bleeding.
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Authors: Hans Michael Kvasnicka, Jürgen Thiele, Carlos E. Bueso-Ramos, William Sun, Jorge Cortes, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Journal of Hematology & Oncology (2018)

Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly, symptom burden, and overall survival in patients with intermediate-2 or high-risk MF compared with placebo or best available therapy (BAT).The effects of ruxolitinib therapy for up to 66 months on BM morphology in 68 patients with advanced MF with variable BM fibrosis grade were compared with those in 192 matching patients treated with BAT. Available trephine biopsies underwent independent, blinded review by three hematopathologists for consensus-based adjudication of grades for reticulin fibrosis, collagen deposition, and osteosclerosis.Ruxolitinib treatment versus BAT was associated with greater odds of BM fibrosis improvement or stabilization and decreased odds of BM fibrosis worsening based on changes from baseline in reticulin fibrosis grade. Generally, these changes were accompanied by a sustained higher level of individual spleen size reduction and regression of leukoerythroblastosis. Patients with more advanced baseline fibrosis showed lower spleen size response.The finding that long-term ruxolitinib therapy may reverse or markedly delay BM fibrosis progression in advanced MF suggests that sustained JAK inhibition may be disease-modifying.INCB18424-251, ClinicalTrials.gov identifier NCT00509899 .
RADIOFREQUENCY ABLATION (RFA) FOR INTRABILIARY EXTENSION OF ADENOMA OF THE PAPILLA OF VATER: PRELIMINARY RESULTS
Authors: A Tringali, V Bove, I Boškoski, G Valerii, R Landi, B Federico, P Familiari, V Perri, G Costamagna
Journal: Endoscopy (2018)

Endoscopic papillectomy of adenoma of the papilla of Vater is an effective technique which can be curative in more than 85% of the cases. Intrabiliary extension of the adenoma can limit the curative intent of the endoscopic resection. Radiofrequency ablation (RFA) of the intraductal extension was evaluated in consecutive patients with adenoma of the papilla of Vater after papillectomy.
OUTCOMES OF ENDOSCOPIC AND SURGICAL REMOVAL OF EARLY COLORECTAL NEOPLASIA
Authors: A Fábián, R Bor, Ö Szabó, M Rutka, B Vasas, L Andrási, A Bálint, K Farkas, Á Milassin, K Szántó, T Molnár, Z Szepes
Journal: Endoscopy (2018)

The best therapeutic approach of early colorectal cancer (CRC) is yet to be defined, and limited data is available on outcomes of endoscopic resection. We aimed to evaluate retrospectively the outcomes of endoscopic and surgical removal of pT1 CRCs between 2012 and 2015 in our tertiary center.